Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird Sells 67,687 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the company’s stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $34.84, for a total value of $2,358,215.08. Following the completion of the sale, the chief operating officer now directly owns 751,243 shares in the company, valued at approximately $26,173,306.12. The trade was a 8.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Melissa Baird also recently made the following trade(s):

• On Wednesday, February 12th, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $44.71, for a total transaction of $3,026,285.77.
• On Tuesday, January 21st, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.35, for a total transaction of $1,986,613.45.

Hims & Hers Health Trading Down 4.2 %

Shares of HIMS stock opened at $31.96 on Friday. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The stock has a market capitalization of $7.10 billion, a P/E ratio of 72.63 and a beta of 1.37. The firm’s 50 day moving average is $39.85 and its 200 day moving average is $29.27.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Bank of America lifted their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday, March 18th. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Leerink Partners raised their price target on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Finally, Truist Financial lifted their price target on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research report on Wednesday, February 26th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average target price of $37.31.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Crewe Advisors LLC bought a new stake in Hims & Hers Health during the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. grew its position in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. increased its stake in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new position in Hims & Hers Health during the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.